Clinical Trials Browser

Active not recruiting × Has results × Gynecologic × Clear all

NCT01167712 2026-04-13

Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

Phase 3 Active not recruiting

692 enrolled 11 charts

Brenner Tumor, Fallopian Tube Neoplasms

NCT02101775 2026-04-13

Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Phase 2 Active not recruiting

124 enrolled 17 charts

Brenner Tumor, Fallopian Tube Neoplasms, Neoplasms, Ovarian Neoplasms

NCT02466971 2026-04-13

Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers

Phase 3 Active not recruiting

450 enrolled 11 charts

Uterine Cervical Neoplasms, Vaginal Neoplasms

NCT02595892 2026-04-13

Gemcitabine Hydrochloride Alone or With M6620 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Phase 2 Active not recruiting

70 enrolled 23 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02627443 2026-04-13

Carboplatin, Gemcitabine Hydrochloride, and Berzosertib in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Phase 1 Active not recruiting

35 enrolled 13 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02839707 2026-04-13

Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 2/3 Active not recruiting

444 enrolled 17 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03348631 2026-04-13

Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer

Phase 2 Active not recruiting

62 enrolled 14 charts

Ovarian Neoplasms

NCT03914612 2026-04-13

Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer

Phase 3 Active not recruiting

813 enrolled 16 charts 2 FDA

GynecologicSarcoma

Carcinosarcoma, Endometrial Neoplasms

NCT04034927 2026-04-13

Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer

Phase 2 Active not recruiting

61 enrolled 15 charts

Fallopian Tube Neoplasms

NCT04287868 2026-04-13

Combination Immunotherapy in Subjects With Advanced HPV Associated Malignancies

Phase 1/2 Active not recruiting

51 enrolled 16 charts

GastrointestinalGynecologicHead & Neck

Anus Neoplasms, Uterine Cervical Neoplasms, Oropharyngeal Neoplasms, Rectal Neoplasms

NCT04739800 2026-04-13

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

Phase 2 Active not recruiting

120 enrolled 19 charts

GenitourinaryGynecologic

Fallopian Tube Mucinous Adenocarcinoma

NCT03428802 2026-04-03

Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability

Phase 2 Active not recruiting

21 enrolled 9 charts

BreastGynecologic

Breast Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms

NCT02873962 2026-04-01

A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib

Phase 2 Active not recruiting

72 enrolled 16 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04905082 2026-03-24

HOPE-Genomics Intervention for the Improvement of Cancer Patient Knowledge of Genomics

Phase NA Active not recruiting

465 enrolled 11 charts

BreastGastrointestinalGenitourinaryGynecologicThoracic

Breast Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms

NCT02655016 2026-03-10

A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

Phase 3 Active not recruiting

733 enrolled 21 charts 3 FDA

Ovarian Neoplasms

NCT05116189 2026-03-09

KEYNOTE-B96

Phase 3 Active not recruiting

643 enrolled 17 charts 3 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT01116648 2026-03-05

Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer

Phase 1/2 Active not recruiting

155 enrolled 34 charts

BreastGynecologic

Fallopian Tube Neoplasms, Triple Negative Breast Neoplasms

NCT02345265 2026-03-05

Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer

Phase 2 Active not recruiting

70 enrolled 16 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02446600 2026-03-05

Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 3 Active not recruiting

579 enrolled 17 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02502266 2026-03-05

Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer

Phase 2/3 Active not recruiting

582 enrolled 21 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03734692 2026-02-12

Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian Cancer

Phase 1/2 Active not recruiting

24 enrolled 59 charts

Ovarian Cancer Recurrent

NCT01081951 2026-02-05

Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer

Phase 2 Active not recruiting

162 enrolled 15 charts

Ovarian Neoplasms

NCT03120624 2026-02-04

VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial Cancer

Phase 1 Active not recruiting

34 enrolled 16 charts

Endometrial Neoplasms

NCT02734004 2026-01-29

MEDIOLA

Phase 1/2 Active not recruiting

264 enrolled 32 charts

BreastGastrointestinalGynecologicThoracic

Breast Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Small Cell Lung Carcinoma

NCT03984695 2026-01-28

SHE-WOMEN

Phase NA Active not recruiting

279 enrolled 17 charts

BreastGynecologic

Breast Neoplasms, Uterine Cervical Neoplasms, Contraception Behavior, Sexually Transmitted Diseases

NCT03671811 2026-01-06

Megestrol Acetate With or Without Pterostilbene in Treating Patients With Endometrial Cancer Undergoing Hysterectomy

Phase 2 Active not recruiting

44 enrolled 12 charts

Endometrial Hyperplasia, Endometrial Neoplasms

NCT03602859 2025-12-31

FIRST

Phase 3 Active not recruiting

1,400 enrolled 18 charts

Ovarian Neoplasms

NCT00565851 2025-12-30

Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Phase 3 Active not recruiting

1,052 enrolled 27 charts

Brenner Tumor, Carcinoma, Adenocarcinoma, Mucinous, Fallopian Tube Neoplasms, Ovarian Neoplasms, Adenocarcinoma, Clear Cell

NCT04269200 2025-12-23

DUO-E

Phase 3 Active not recruiting

805 enrolled 18 charts 2 FDA

Endometrial Neoplasms

NCT04670068 2025-12-22

Phase I Study of Autologous CAR T-Cells Targeting the B7-H3 Antigen in Recurrent Epithelial Ovarian

Phase 1 Active not recruiting

4 enrolled 8 charts

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT04579380 2025-12-19

Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations

Phase 2 Active not recruiting

217 enrolled 19 charts

BreastGastrointestinalGenitourinaryGynecologicThoracic

Biliary Tract Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Urologic Neoplasms, Uterine Neoplasms, Colorectal Neoplasms

NCT05276973 2025-12-19

Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer

Phase 1 Active not recruiting

25 enrolled 14 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT01844986 2025-12-10

SOLO-1

Phase 3 Active not recruiting

450 enrolled 18 charts 2 FDA

Pathologic Complete Response, Ovarian Neoplasms

NCT01081262 2025-11-25

Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer

Phase 3 Active not recruiting

50 enrolled 13 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05696444 2025-11-25

Medtronic Hugo™ Robotic Assisted Surgery (RAS) System in Urologic Surgery (Expand URO)

Phase NA Active not recruiting

144 enrolled 22 charts

GenitourinaryGynecologic

Congenital Abnormalities, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Kidney Failure, Chronic, Kidney Neoplasms, Pelvic Neoplasms, Prostatic Neoplasms, Cystitis, Interstitial

NCT01068249 2025-11-18

Letrozole and RAD001 With Advanced or Recurrent Endometrial Cancer

Phase 2 Active not recruiting

42 enrolled 11 charts

Recurrence, Endometrial Neoplasms

NCT02068794 2025-11-18

MV-NIS Infected Mesenchymal Stem Cells in Treating Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer

Phase 1/2 Active not recruiting

34 enrolled 12 charts

Brenner Tumor, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02142803 2025-11-13

TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors

Phase 1 Active not recruiting

50 enrolled 16 charts

Fallopian Tube Neoplasms, Glioblastoma, Ovarian Neoplasms

NCT02595879 2025-11-13

Triapine With Chemotherapy and Radiation Therapy in Treating Patients With IB2-IVA Cervical or Vaginal Cancer

Phase 1 Active not recruiting

21 enrolled 22 charts

Uterine Cervical Neoplasms

NCT00977574 2025-10-31

Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

Phase 2 Active not recruiting

349 enrolled 11 charts

GynecologicSarcoma

Endometrial Adenocarcinoma

NCT03740165 2025-10-22

KEYLYNK-001

Phase 3 Active not recruiting

1,367 enrolled 29 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

NCT05708703 2025-09-16

Assessing the Time Demands of Cancer

Active not recruiting

78 enrolled 8 charts

BreastGynecologic

Breast Neoplasms, Ovarian Neoplasms

NCT01012817 2025-09-15

Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer

Phase 1/2 Active not recruiting

88 enrolled 23 charts

Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms

NCT02257528 2025-09-08

Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer

Phase 2 Active not recruiting

26 enrolled 12 charts

Uterine Cervical Neoplasms

NCT00788671 2025-08-15

Levonorgestrel-Releasing Intrauterine System in Treating Patients With Complex Atypical Hyperplasia or Grade I Endometrial Cancer

Phase 2 Active not recruiting

69 enrolled 10 charts

Endometrial Hyperplasia

NCT01874353 2025-08-03

Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy

Phase 3 Active not recruiting

327 enrolled 21 charts 2 FDA

Ovarian Neoplasms

NCT01696994 2025-07-23

Screening for Ovarian Cancer in Older Patients (PLCO Screening Trial)

Phase NA Active not recruiting

78,216 enrolled 23 charts

Ovarian Neoplasms

NCT03113487 2025-07-20

P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Phase 2 Active not recruiting

29 enrolled 11 charts

Recurrent Platinum-Resistant Fallopian Tube Carcinoma

NCT02912572 2025-07-10

Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer

Phase 2 Active not recruiting

106 enrolled 16 charts

Endometrial Neoplasms

NCT03522246 2025-06-24

ATHENA

Phase 3 Active not recruiting

1,097 enrolled 26 charts

Carcinoma, Ovarian Epithelial, Pathologic Complete Response, Fallopian Tube Neoplasms, Neoplasms